Asthma Exacerbations: Pathogenesis, Prevention, and Treatment

Journal of Allergy and Clinical Immunology: In Practice

Volumn 5, Issue 4, 2017, Pages 918-927

  Castillo, Jamee R ^a   Peters, Stephen P ^b   Busse, William W ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Allergy; Anti IgE; Anti IL5; Anticholinergics; Asthma; Asthma exacerbation; Inhaled corticosteroids; Leukotriene antagonist; Long acting 2 agonists; Prevention; Systemic corticosteroids; Treatment; Viral infection

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEPOLIZUMAB; OMALIZUMAB; RESLIZUMAB; TIOTROPIUM BROMIDE; ANTIASTHMATIC AGENT;

2009 H1N1 INFLUENZA; ADENOVIRUS INFECTION; AIR POLLUTION; ALLERGENICITY; ARTICLE; ASTHMA; BACTERIAL INFECTION; BIOLOGICAL THERAPY; BOCAVIRUS INFECTION; CORONAVIRUS INFECTION; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; ENVIRONMENTAL EXPOSURE; HUMAN METAPNEUMOVIRUS INFECTION; MUCOCILIARY CLEARANCE; PARAINFLUENZA VIRUS INFECTION; PATHOGENESIS; PATIENT CARE; PRACTICE GUIDELINE; PROPHYLAXIS; RHINOVIRUS INFECTION; RISK FACTOR; SENSITIZATION; SUSPENDED PARTICULATE MATTER; VIRAL RESPIRATORY TRACT INFECTION; VIRUS IMMUNITY; HUMAN;

ANTI-ASTHMATIC AGENTS; ASTHMA; BIOLOGICAL THERAPY; HUMANS;

EID: 85021838840     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2017.05.001     Document Type: Article

References (137)

1. Bai, T.R., Vonk, J.M., Postma, D.S., Boezen, H.M., Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 30 (2007), 452–456.
2. O'Byrne, P.M., Pedersen, S., Lamm, C.J., Tan, W.C., Busse, W.W., Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 179 (2009), 19–24.
3. Ivanova, J.I., Bergman, R., Birnbaum, H.G., Colice, G.L., Silverman, R.A., McLaurin, K., Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immunol 129 (2012), 1229–1235.
4. Barnett, S.B., Nurmagambetov, T.A., Costs of asthma in the United States: 2002-2007. J Allergy Clin Immunol 127 (2011), 145–152.
5. Miller, M.K., Lee, J.H., Miller, D.P., Wenzel, S.E., Group, T.S., Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med 101 (2007), 481–489.
6. Johnston, S.L., Pattemore, P.K., Sanderson, G., Smith, S., Lampe, F., Josephs, L., et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 310 (1995), 1225–1229.
7. Nicholson, K.G., Kent, J., Ireland, D.C., Respiratory viruses and exacerbations of asthma in adults. BMJ 307 (1993), 982–986.
8. Johnston, S.L., Pattemore, P.K., Sanderson, G., Smith, S., Campbell, M.J., Josephs, L.K., et al. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med 154 (1996), 654–660.
9. Johnston, N.W., Johnston, S.L., Norman, G.R., Dai, J., Sears, M.R., The September epidemic of asthma hospitalization: school children as disease vectors. J Allergy Clin Immunol 117 (2006), 557–562.
10. O'Riordan, S., Barton, M., Yau, Y., Read, S.E., Allen, U., Tran, D., Risk factors and outcomes among children admitted to hospital with pandemic H1N1 influenza. CMAJ 182 (2010), 39–44.
11. Plessa, E., Diakakis, P., Gardelis, J., Thirios, A., Koletsi, P., Falagas, M.E., Clinical features, risk factors, and complications among pediatric patients with pandemic influenza A (H1N1). Clin Pediatr (Phila) 49 (2010), 777–781.
12. Libster, R., Bugna, J., Coviello, S., Hijano, D.R., Dunaiewsky, M., Reynoso, N., et al. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N Engl J Med 362 (2010), 45–55.
13. Falsey, A.R., Hennessey, P.A., Formica, M.A., Cox, C., Walsh, E.E., Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352 (2005), 1749–1759.
14. Yoo, J.K., Kim, T.S., Hufford, M.M., Braciale, T.J., Viral infection of the lung: host response and sequelae. J Allergy Clin Immunol 132 (2013), 1263–1276 quiz 77.
15. Bateman, E.D., Buhl, R., O'Byrne, P.M., Humbert, M., Reddel, H.K., Sears, M.R., et al. Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations. J Allergy Clin Immunol 135 (2015), 1457–1464.e4.
16. Soto-Quiros, M., Avila, L., Platts-Mills, T.A., Hunt, J.F., Erdman, D.D., Carper, H., et al. High titers of IgE antibody to dust mite allergen and risk for wheezing among asthmatic children infected with rhinovirus. J Allergy Clin Immunol 129 (2012), 1499–1505.e5.
17. MacMicking, J.D., Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat Rev Immunol 12 (2012), 367–382.
18. Papadopoulos, N.G., Stanciu, L.A., Papi, A., Holgate, S.T., Johnston, S.L., Rhinovirus-induced alterations on peripheral blood mononuclear cell phenotype and costimulatory molecule expression in normal and atopic asthmatic subjects. Clin Exp Allergy 32 (2002), 537–542.
19. Gehlhar, K., Bilitewski, C., Reinitz-Rademacher, K., Rohde, G., Bufe, A., Impaired virus-induced interferon-alpha2 release in adult asthmatic patients. Clin Exp Allergy 36 (2006), 331–337.
20. Teach, S.J., Gill, M.A., Togias, A., Sorkness, C.A., Arbes, S.J. Jr., Calatroni, A., et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol 136 (2015), 1476–1485.
21. Gill, M.A., Bajwa, G., George, T.A., Dong, C.C., Dougherty, I.I., Jiang, N., et al. Counterregulation between the FcepsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells. J Immunol 184 (2010), 5999–6006.
22. Wark, P.A., Johnston, S.L., Bucchieri, F., Powell, R., Puddicombe, S., Laza-Stanca, V., et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 201 (2005), 937–947.
23. Baraldo, S., Contoli, M., Bazzan, E., Turato, G., Padovani, A., Marku, B., et al. Deficient antiviral immune responses in childhood: distinct roles of atopy and asthma. J Allergy Clin Immunol 130 (2012), 1307–1314.
24. Djukanovic, R., Harrison, T., Johnston, S.L., Gabbay, F., Wark, P., Thomson, N.C., et al. The effect of inhaled IFN-beta on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med 190 (2014), 145–154.
25. Von, H.L., Role of persistent infection in the control and severity of asthma: focus on Chlamydia pneumoniae. Eur Respir J 19 (2002), 546–556.
26. Martin, R.J., Kraft, M., Chu, H.W., Berns, E.A., Cassell, G.H., A link between chronic asthma and chronic infection. J Allergy Clin Immunol 107 (2001), 595–601.
27. Oliver, B.G., Lim, S., Wark, P., Laza-Stanca, V., King, N., Black, J.L., et al. Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages. Thorax 63 (2008), 519–525.
28. Zureik, M., Neukirch, C., Leynaert, B., Liard, R., Bousquet, J., Neukirch, F., Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey. BMJ 325 (2002), 411–414.
29. Sporik, R., Holgate, S.T., Platts-Mills, T.A., Cogswell, J.J., Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N Engl J Med 323 (1990), 502–507.
30. Permaul, P., Hoffman, E., Fu, C., Sheehan, W., Baxi, S., Gaffin, J., et al. Allergens in urban schools and homes of children with asthma. Pediatr Allergy Immunol 23 (2012), 543–549.
31. Olivieri, M., Zock, J.P., Accordini, S., Heinrich, J., Jarvis, D., Kunzli, N., et al. Risk factors for new-onset cat sensitization among adults: a population-based international cohort study. J Allergy Clin Immunol 129 (2012), 420–425.
32. Samoli, E., Nastos, P.T., Paliatsos, A.G., Katsouyanni, K., Priftis, K.N., Acute effects of air pollution on pediatric asthma exacerbation: evidence of association and effect modification. Environ Res 111 (2011), 418–424.
33. Trasande, L., Thurston, G.D., The role of air pollution in asthma and other pediatric morbidities. J Allergy Clin Immunol 115 (2005), 689–699.
34. Message, S.D., Laza-Stanca, V., Mallia, P., Parker, H.L., Zhu, J., Kebadze, T., et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci USA 105 (2008), 13562–13567.
35. Gergen, P.J., Turkeltaub, P.C., The association of individual allergen reactivity with respiratory disease in a national sample: data from the second National Health and Nutrition Examination Survey, 1976-80 (NHANES II). J Allergy Clin Immunol 90 (1992), 579–588.
36. Downs, S.H., Mitakakis, T.Z., Marks, G.B., Car, N.G., Belousova, E.G., Leuppi, J.D., et al. Clinical importance of Alternaria exposure in children. Am J Respir Crit Care Med 164 (2001), 455–459.
37. Rosas, I., McCartney, H.A., Payne, R.W., Calderon, C., Lacey, J., Chapela, R., et al. Analysis of the relationships between environmental factors (aeroallergens, air pollution, and weather) and asthma emergency admissions to a hospital in Mexico City. Allergy 53 (1998), 394–401.
38. O'Hollaren, M.T., Yunginger, J.W., Offord, K.P., Somers, M.J., O'Connell, E.J., Ballard, D.J., et al. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. N Engl J Med 324 (1991), 359–363.
39. Copenhaver, C.C., Gern, J.E., Li, Z., Shult, P.A., Rosenthal, L.A., Mikus, L.D., et al. Cytokine response patterns, exposure to viruses, and respiratory infections in the first year of life. Am J Respir Crit Care Med 170 (2004), 175–180.
40. Eisner, M.D., Klein, J., Hammond, S.K., Koren, G., Lactao, G., Iribarren, C., Directly measured second hand smoke exposure and asthma health outcomes. Thorax 60 (2005), 814–821.
41. Thomson, N.C., Chaudhuri, R., Livingston, E., Asthma and cigarette smoking. Eur Respir J 24 (2004), 822–833.
42. Hansel, N.N., Breysse, P.N., McCormack, M.C., Matsui, E.C., Curtin-Brosnan, J., Williams, D.L., et al. A longitudinal study of indoor nitrogen dioxide levels and respiratory symptoms in inner-city children with asthma. Environ Health Perspect 116 (2008), 1428–1432.
43. Castro, M., Zimmermann, N.A., Crocker, S., Bradley, J., Leven, C., Schechtman, K.B., Asthma intervention program prevents readmissions in high healthcare users. Am J Respir Crit Care Med 168 (2003), 1095–1099.
44. Janson, S.L., McGrath, K.W., Covington, J.K., Cheng, S.C., Boushey, H.A., Individualized asthma self-management improves medication adherence and markers of asthma control. J Allergy Clin Immunol 123 (2009), 840–846.
45. Clark, J.M., Abraham, W.M., Fishman, C.E., Forteza, R., Ahmed, A., Cortes, A., et al. Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep. Am J Respir Crit Care Med 152 (1995), 2076–2083.
46. Cockcroft, D.W., Killian, D.N., Mellon, J.J., Hargreave, F.E., Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 7 (1977), 235–243.
47. Juniper, E.F., Kline, P.A., Vanzieleghem, M.A., Ramsdale, E.H., O'Byrne, P.M., Hargreave, F.E., Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 142 (1990), 832–836.
48. Juniper, E.F., Kline, P.A., Vanzieleghem, M.A., Ramsdale, E.H., O'Byrne, P.M., Hargreave, F.E., Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur Respir J 3 (1990), 1122–1127.
49. Dahl, R., Lundback, B., Malo, J.L., Mazza, J.A., Nieminen, M.M., Saarelainen, P., et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group. Chest 104 (1993), 1352–1358.
50. Pauwels, R.A., Lofdahl, C.G., Postma, D.S., Tattersfield, A.E., O'Byrne, P., Barnes, P.J., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 337 (1997), 1405–1411.
51. O'Byrne, P.M., Barnes, P.J., Rodriguez-Roisin, R., Runnerstrom, E., Sandstrom, T., Svensson, K., et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 164 (2001), 1392–1397.
52. Busse, W.W., Chervinsky, P., Condemi, J., Lumry, W.R., Petty, T.L., Rennard, S., et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 101 (1998), 457–463.
53. Sin, D.D., Man, J., Sharpe, H., Gan, W.Q., Man, S.F., Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA 292 (2004), 367–376.
54. Bisgaard, H., Use of inhaled corticosteroids in pediatric asthma. Pediatr Pulmonol Suppl 15 (1997), 27–33.
55. Covar, R.A., Szefler, S.J., Zeiger, R.S., Sorkness, C.A., Moss, M., Mauger, D.T., et al. Factors associated with asthma exacerbations during a long-term clinical trial of controller medications in children. J Allergy Clin Immunol 122 (2008), 741–747.
56. Oborne, J., Mortimer, K., Hubbard, R.B., Tattersfield, A.E., Harrison, T.W., Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Am J Respir Crit Care Med 180 (2009), 598–602.
57. FitzGerald, J.M., Becker, A., Sears, M.R., Mink, S., Chung, K., Lee, J., Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 59 (2004), 550–556.
58. Harrison, T.W., Oborne, J., Newton, S., Tattersfield, A.E., Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 363 (2004), 271–275.
59. Ducharme, F.M., Lemire, C., Noya, F.J., Davis, G.M., Alos, N., Leblond, H., et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N Engl J Med 360 (2009), 339–353.
60. Gibson, P.G., Saltos, N., Borgas, T., Airway mast cells and eosinophils correlate with clinical severity and airway hyperresponsiveness in corticosteroid-treated asthma. J Allergy Clin Immunol 105 (2000), 752–759.
61. Brightling, C.E., Green, R.H., Pavord, I.D., Biomarkers predicting response to corticosteroid therapy in asthma. Treat Respir Med 4 (2005), 309–316.
62. Turner, M.O., Hussack, P., Sears, M.R., Dolovich, J., Hargreave, F.E., Exacerbations of asthma without sputum eosinophilia. Thorax 50 (1995), 1057–1061.
63. Green, R.H., Brightling, C.E., McKenna, S., Hargadon, B., Parker, D., Bradding, P., et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360 (2002), 1715–1721.
64. Jayaram, L., Pizzichini, M.M., Cook, R.J., Boulet, L.P., Lemiere, C., Pizzichini, E., et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 27 (2006), 483–494.
65. Haldar, P., Brightling, C.E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360 (2009), 973–984.
66. Nair, P., Pizzichini, M.M., Kjarsgaard, M., Inman, M.D., Efthimiadis, A., Pizzichini, E., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360 (2009), 985–993.
67. Fahy, J.V., Kim, K.W., Liu, J., Boushey, H.A., Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 95 (1995), 843–852.
68. Cox, G., Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol 154 (1995), 4719–4725.
69. Bateman, E.D., Boushey, H.A., Bousquet, J., Busse, W.W., Clark, T.J., Pauwels, R.A., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 170 (2004), 836–844.
70. Stanford, R.H., Fuhlbrigge, A., Riedel, A., Rey, G.G., Stempel, D.A., An observational study of fixed dose combination fluticasone propionate/salmeterol or fluticasone propionate alone on asthma-related outcomes. Curr Med Res Opin 24 (2008), 3141–3148.
71. Papi, A., Paggiaro, P.L., Nicolini, G., Vignola, A.M., Fabbri, L.M., Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J 29 (2007), 682–689.
72. O'Byrne, P.M., Bisgaard, H., Godard, P.P., Pistolesi, M., Palmqvist, M., Zhu, Y., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171 (2005), 129–136.
73. Rabe, K.F., Atienza, T., Magyar, P., Larsson, P., Jorup, C., Lalloo, U.G., Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 368 (2006), 744–753.
74. Bousquet, J., Boulet, L.P., Peters, M.J., Magnussen, H., Quiralte, J., Martinez-Aguilar, N.E., et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 101 (2007), 2437–2446.
75. Bisgaard, H., Le Roux, P., Bjamer, D., Dymek, A., Vermeulen, J.H., Hultquist, C., Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 130 (2006), 1733–1743.
76. Palmqvist, M., Persson, G., Lazer, L., Rosenborg, J., Larsson, P., Lotvall, J., Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 10 (1997), 2484–2489.
77. Balanag, V.M., Yunus, F., Yang, P.C., Jorup, C., Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm Pharmacol Ther 19 (2006), 139–147.
78. Palmqvist, M., Ibsen, T., Mellen, A., Lotvall, J., Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 160 (1999), 244–249.
79. Kelly, M.M., O'Connor, T.M., Leigh, R., Otis, J., Gwozd, C., Gauvreau, G.M., et al. Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma. J Allergy Clin Immunol 125 (2010), 349–356.e13.
80. Edwards, M.R., Johnson, M.W., Johnston, S.L., Combination therapy: synergistic suppression of virus-induced chemokines in airway epithelial cells. Am J Respir Cell Mol Biol 34 (2006), 616–624.
81. Johnston, N.W., Mandhane, P.J., Dai, J., Duncan, J.M., Greene, J.M., Lambert, K., et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics 120 (2007), e702–e712.
82. Reiss, T.F., Chervinsky, P., Dockhorn, R.J., Shingo, S., Seidenberg, B., Edwards, T.B., Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 158 (1998), 1213–1220.
83. Bjermer, L., Bisgaard, H., Bousquet, J., Fabbri, L.M., Greening, A.P., Haahtela, T., et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ, 327, 2003, 891.
84. Weiss, K.B., Gern, J.E., Johnston, N.W., Sears, M.R., Jones, C.A., Jia, G., et al. The Back to School asthma study: the effect of montelukast on asthma burden when initiated prophylactically at the start of the school year. Ann Allergy Asthma Immunol 105 (2010), 174–181.
85. Price, D.B., Hernandez, D., Magyar, P., Fiterman, J., Beeh, K.M., James, I.G., et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 58 (2003), 211–216.
86. Kerstjens, H.A., Engel, M., Dahl, R., Paggiaro, P., Beck, E., Vandewalker, M., et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 367 (2012), 1198–1207.
87. Rodrigo, G.J., Castro-Rodriguez, J.A., What is the role of tiotropium in asthma?: A systematic review with meta-analysis. Chest 147 (2015), 388–396.
88. Szefler, S.J., Murphy, K., Harper, T. III, Boner, A., Laki, I., Engel, M., et al. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. [e-pub ahead of print] J Allergy Clin Immunol, 2017, 10.1016/j.jaci.2017.01.014.
89. Quezada, W., Kwak, E.S., Reibman, J., Rogers, L., Mastronarde, J., Teague, W.G., et al. Predictors of asthma exacerbation among patients with poorly controlled asthma despite inhaled corticosteroid treatment. Ann Allergy Asthma Immunol 116 (2016), 112–117.
90. Carter, M.C., Perzanowski, M.S., Raymond, A., Platts-Mills, T.A., Home intervention in the treatment of asthma among inner-city children. J Allergy Clin Immunol 108 (2001), 732–737.
91. Irvine, L., Crombie, I.K., Clark, R.A., Slane, P.W., Feyerabend, C., Goodman, K.E., et al. Advising parents of asthmatic children on passive smoking: randomised controlled trial. BMJ 318 (1999), 1456–1459.
92. Morgan, W.J., Crain, E.F., Gruchalla, R.S., O'Connor, G.T., Kattan, M., Evans, R. III, et al. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med 351 (2004), 1068–1080.
93. Busse, W., Corren, J., Lanier, B.Q., McAlary, M., Fowler-Taylor, A., Cioppa, G.D., et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108 (2001), 184–190.
94. Busse, W.W., Massanari, M., Kianifard, F., Geba, G.P., Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. Curr Med Res Opin 23 (2007), 2379–2386.
95. Ohta, K., Miyamoto, T., Amagasaki, T., Yamamoto, M., Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. Respirology 14 (2009), 1156–1165.
96. Hanania, N.A., Alpan, O., Hamilos, D.L., Condemi, J.J., Reyes-Rivera, I., Zhu, J., et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 154 (2011), 573–582.
97. Walker, S., Monteil, M., Phelan, K., Lasserson, T.J., Walters, E.H., Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev, 19, 2006, Cd003559.
98. Rees, P.J., Review: omalizumab reduces exacerbation and steroid use in chronic asthma. Arch Dis Child Educ Pract Ed, 92, 2007, ep127.
99. Busse, W.W., Morgan, W.J., Gergen, P.J., Mitchell, H.E., Gern, J.E., Liu, A.H., et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 364 (2011), 1005–1015.
100. Lanier, B., Bridges, T., Kulus, M., Taylor, A.F., Berhane, I., Vidaurre, C.F., Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 124 (2009), 1210–1216.
101. Massanari, M., Milgrom, H., Pollard, S., Maykut, R.J., Kianifard, F., Fowler-Taylor, A., et al. Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate—severe allergic asthma. Clin Pediatr (Phila) 48 (2009), 859–865.
102. Hanania, N.A., Wenzel, S., Rosen, K., Hsieh, H.J., Mosesova, S., Choy, D.F., et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 187 (2013), 804–811.
103. CONTROLLED trial of effects of cortisone acetate in status asthmaticus; report to the Medical Research Council by the subcommittee on clinical trials in asthma. Lancet 271 (1956), 803–806.
104. Price, D.B., Rigazio, A., Campbell, J.D., Bleecker, E.R., Corrigan, C.J., Thomas, M., et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 3 (2015), 849–858.
105. Pavord, I.D., Korn, S., Howarth, P., Bleecker, E.R., Buhl, R., Keene, O.N., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380 (2012), 651–659.
106. Bel, E.H., Wenzel, S.E., Thompson, P.J., Prazma, C.M., Keene, O.N., Yancey, S.W., et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371 (2014), 1189–1197.
107. Ortega, H.G., Yancey, S.W., Mayer, B., Gunsoy, N.B., Keene, O.N., Bleecker, E.R., et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 4 (2016), 549–556.
108. Castro, M., Mathur, S., Hargreave, F., Boulet, L.P., Xie, F., Young, J., et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 184 (2011), 1125–1132.
109. Castro, M., Zangrilli, J., Wechsler, M.E., Bateman, E.D., Brusselle, G.G., Bardin, P., et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3 (2015), 355–366.
110. Jackson, D.J., Makrinioti, H., Rana, B.M., Shamji, B.W., Trujillo-Torralbo, M.B., Footitt, J., et al. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med 190 (2014), 1373–1382.
111. Kelly, H.W., Levalbuterol for asthma: a better treatment?. Curr Allergy Asthma Rep 7 (2007), 310–314.
112. Rodrigo, G., Rodrigo, C., Corticosteroids in the emergency department therapy of acute adult asthma: an evidence-based evaluation. Chest 116 (1999), 285–295.
113. Rowe, B.H., Spooner, C., Ducharme, F.M., Bretzlaff, J.A., Bota, G.W., Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev(1), 2001, CD002178.
114. Camargo, C.A. Jr., Spooner, C.H., Rowe, B.H., Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev(4), 2003, CD001115.
115. Rodrigo, G.J., Rodrigo, C., Continuous vs intermittent beta-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis. Chest 122 (2002), 160–165.
116. Camargo, C.A. Jr., Rachelefsky, G., Schatz, M., Managing asthma exacerbations in the emergency department: summary of the National Asthma Education and Prevention Program Expert Panel Report 3 guidelines for the management of asthma exacerbations. Proc Am Thorac Soc 6 (2009), 357–366.
117. Cates, C.J., Welsh, E.J., Rowe, B.H., Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev(9), 2013, CD000052.
118. Hasegawa, K., Sullivan, A.F., Tovar Hirashima, E., Gaeta, T.J., Fee, C., Turner, S.J., et al. A multicenter observational study of US adults with acute asthma: who are the frequent users of the emergency department?. J Allergy Clin Immunol Pract 2 (2014), 733–740.
119. Qureshi, F., Pestian, J., Davis, P., Zaritsky, A., Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med 339 (1998), 1030–1035.
120. Rodrigo, G.J., Castro-Rodriguez, J.A., Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax 60 (2005), 740–746.
121. Zorc, J.J., Pusic, M.V., Ogborn, C.J., Lebet, R., Duggan, A.K., Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics 103 (1999), 748–752.
122. Krishnan, J.A., Davis, S.Q., Naureckas, E.T., Gibson, P., Rowe, B.H., An umbrella review: corticosteroid therapy for adults with acute asthma. Am J Med 122 (2009), 977–991.
123. Rodrigo, G.J., Rapid effects of inhaled corticosteroids in acute asthma: an evidence-based evaluation. Chest 130 (2006), 1301–1311.
124. Schuh, S., Reisman, J., Alshehri, M., Dupuis, A., Corey, M., Arseneault, R., et al. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. N Engl J Med 343 (2000), 689–694.
125. Lee-Wong, M., Dayrit, F.M., Kohli, A.R., Acquah, S., Mayo, P.H., Comparison of high-dose inhaled flunisolide to systemic corticosteroids in severe adult asthma. Chest 122 (2002), 1208–1213.
126. Levy, M.L., Stevenson, C., Maslen, T., Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care. Thorax 51 (1996), 1087–1092.
127. Rodrigo, G.J., Comparison of inhaled fluticasone with intravenous hydrocortisone in the treatment of adult acute asthma. Am J Respir Crit Care Med 171 (2005), 1231–1236.
128. Edmonds, M.L., Milan, S.J., Brenner, B.E., Camargo, C.A. Jr., Rowe, B.H., Inhaled steroids for acute asthma following emergency department discharge. Cochrane Database Syst Rev, 12, 2012, Cd002316.
129. Rowe, B.H., Edmonds, M.L., Spooner, C.H., Diner, B., Camargo, C.A. Jr., Corticosteroid therapy for acute asthma. Respir Med 98 (2004), 275–284.
130. Fanta, C.H., Rossing, T.H., McFadden, E.R. Jr., Glucocorticoids in acute asthma. A critical controlled trial. Am J Med 74 (1983), 845–851.
131. Manser, R., Reid, D., Abramson, M., Corticosteroids for acute severe asthma in hospitalised patients. Cochrane Database Syst Rev(1), 2001, CD001740.
132. Marquette, C.H., Stach, B., Cardot, E., Bervar, J.F., Saulnier, F., Lafitte, J.J., et al. High-dose and low-dose systemic corticosteroids are equally efficient in acute severe asthma. Eur Respir J 8 (1995), 22–27.
133. Becker, J.M., Arora, A., Scarfone, R.J., Spector, N.D., Fontana-Penn, M.E., Gracely, E., et al. Oral versus intravenous corticosteroids in children hospitalized with asthma. J Allergy Clin Immunol 103 (1999), 586–590.
134. Ratto, D., Alfaro, C., Sipsey, J., Glovsky, M.M., Sharma, O.P., Are intravenous corticosteroids required in status asthmaticus?. JAMA 260 (1988), 527–529.
135. Jones, A.M., Munavvar, M., Vail, A., Aldridge, R.E., Hopkinson, L., Rayner, C., et al. Prospective, placebo-controlled trial of 5 vs 10 days of oral prednisolone in acute adult asthma. Respir Med 96 (2002), 950–954.
136. Altamimi, S., Robertson, G., Jastaniah, W., Davey, A., Dehghani, N., Chen, R., et al. Single-dose oral dexamethasone in the emergency management of children with exacerbations of mild to moderate asthma. Pediatr Emerg Care 22 (2006), 786–793.
137. Nowak, R.M., Parker, J.M., Silverman, R.A., Rowe, B.H., Smithline, H., Khan, F., et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. Am J Emerg Med 33 (2015), 14–20.